J Neurogastroenterol Motil.  2014 Jan;20(1):6-16.

New and Future Drug Development for Gastroesophageal Reflux Disease

Affiliations
  • 1The Esophageal and Swallowing Center, Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA. ronnie.fass@gmail.com

Abstract

Medical therapy remains the most popular treatment for gastroesophageal reflux disease (GERD). Whilst interest in drug development for GERD has declined over the last few years primarily due to the conversion of most proton pump inhibitor (PPI)'s to generic and over the counter compounds, there are still numerous areas of unmet needs in GERD. Drug development has been focused on potent histamine type 2 receptor antagonist's, extended release PPI's, PPI combination, potassium-competitive acid blockers, transient lower esophageal sphincter relaxation reducers, prokinetics, mucosal protectants and esophageal pain modulators. It is likely that the aforementioned compounds will be niched for specific areas of unmet need in GERD, rather than compete with the presently available anti-reflux therapies.

Keyword

Erosive esophagitis; Gastroesophageal reflux; Heartburn; Proton pump inhibitors

MeSH Terms

Esophageal Sphincter, Lower
Gastroesophageal Reflux*
Heartburn
Histamine
Proton Pump Inhibitors
Proton Pumps
Relaxation
Histamine
Proton Pump Inhibitors
Proton Pumps
Full Text Links
  • JNM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr